D-0309-2021 Class III Terminated

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-0309-2021 was initiated by Teva Pharmaceuticals USA on Mar 4, 2021 and is designated Class III. Reason for recall: Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing. The recall status is terminated (terminated May 19, 2022). Affected quantity: 1,416 vials.

Recall details

Product Type
Drugs
Report Date
Mar 24, 2021
Initiation Date
Mar 4, 2021
Termination Date
May 19, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1,416 vials

Product description

Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01

Reason for recall

Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.

Distribution pattern

Distributed Nationwide in the USA.

Code information

Lot # 31328184C, exp. date 11/2021 Lot # 31327686C, exp. date 08/2021 Lot # 31327685C, exp. date 08/2021

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0309-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0309-2021. Report a data issue: hello@regdatalab.com.